Top Suppliers:I want be here
Related CAS#:
134523-00-5 110862-48-1
125971-58-6 1391052-82-6
693793-53-2 887196-30-7
204696-52-6 501121-34-2
134523-01-6 125995-03-1
1780723-29-6 1310105-54-4
1158522-08-7 1243379-94-3
1421442-66-1 940364-43-2
1788677-98-4 1428118-52-8
134104-43-1 131615-57-1

134523-00-5

134523-00-5 structure
134523-00-5 structure
  • Name: Atorvastatin
  • Chemical Name: atorvastatin
  • CAS Number: 134523-00-5
  • Molecular Formula: C33H35FN2O5
  • Molecular Weight: 558.64
  • Catalog: API Circulatory system medication Regulating blood lipids
  • Create Date: 2018-03-19 08:00:00
  • Modify Date: 2024-01-02 08:12:04
  • Atorvastatin is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. Target: HMG-CoA reductaseAtorvastatin is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. 81 patients were randomly assigned to receive either placebo or 2.5, 5, 10, 20, 40, or 80 mg atorvastatin once daily for 6 weeks. Plasma LDL cholesterol reductions from baseline were dose related, with 25% to 61% reduction from the minimum dose to the maximum dose of 80 mg atorvastatin once a day [1]. Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins [2].
Name atorvastatin
Synonyms (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
[R-( R*,R*)]-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
Atorvastatin
(3R,5R)-7-{2-(4-Fluorophenyl)-4-[(Z)-hydroxy(phenylimino)methyl]-5-isopropyl-3-phenyl-1H-pyrrol-1-yl}-3,5-dihydroxyheptanoic acid
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (βR,δR)-rel-
(3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (βR,δR)-
MFCD03613598
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-4-[(Z)-hydroxy(phenylimino)methyl]-5-(1-methylethyl)-3-phenyl-, (βR,δR)-
Description Atorvastatin is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. Target: HMG-CoA reductaseAtorvastatin is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. 81 patients were randomly assigned to receive either placebo or 2.5, 5, 10, 20, 40, or 80 mg atorvastatin once daily for 6 weeks. Plasma LDL cholesterol reductions from baseline were dose related, with 25% to 61% reduction from the minimum dose to the maximum dose of 80 mg atorvastatin once a day [1]. Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins [2].
Related Catalog
References

[1]. Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82.

[2]. Colhoun, H.M., et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004. 364(9435): p. 685-96.
Density 1.2±0.1 g/cm3
Boiling Point 722.2±60.0 °C at 760 mmHg
Melting Point 176-178°C
Molecular Formula C33H35FN2O5
Molecular Weight 558.64
Flash Point 390.6±32.9 °C
PSA 229.24000
LogP 4.13
Vapour Pressure 0.0±2.5 mmHg at 25°C
Index of Refraction 1.603
Hazard Codes Xn
Risk Phrases R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases S26-S36/37/39-S45
RIDADR UN 3261 8/PG 2
WGK Germany 2
Packaging Group III
Hazard Class 8
HS Code 2942000000
HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Chemsrc provides CAS#:134523-00-5 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 134523-00-5 | Chemsrc address: https://www.chemsrc.com/en/baike/1026737.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved